Skip to main content
Add Me To Your Mailing List

ChemPharma® Professional Association
Bringing experienced business and technical professionals from chemical, pharmaceutical, biotechnology, life sciences, and allied industries together to foster career and personal success through sharing information and building relationships.
We network for success!

 

Upcoming Events
Upcoming Events

 


HomeEventsPCCI Presents SFA Therapeutics, LLC A Development-Stage Bio-Pharmaceutical Startup Company

Events - Event View

This is the "Event Detail" view, showing all available information for this event. If the event has passed, click the "Event Report" button to read a report and view photos that were uploaded.

PCCI Presents SFA Therapeutics, LLC A Development-Stage Bio-Pharmaceutical Startup Company

When:
Monday, November 13, 2017, 6:00 PM until 10:00 PM
Where:
Embassy Suites
Chesterbrook
888 Chesterbrook Blvd
Chesterbrook, PA  19087
Additional Info:
Category:
non-CPPA event
Registration is required
Payment In Advance Only
Registrants & Fees
$40.00
$50.00
$40.00
$50.00

SFA Therapeutics, LLC is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment of inflammatory diseases, targeting NF-Kb. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease (IBD), Crohn's Disease, Psoriasis, Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), and even cancer. SFA’s microbiome-derived drugs are derived from natural substances identified at Temple University, and enable a new platform for developing treatments potentially aimed at over 100 inflammatory diseases currently afflicting patients; with safer treatments than current therapies. Their initial focus is in Psoriasis and Liver Disease (Hepatitis B, NASH and HCC). Patents have been filed in both of these diseases, based on animal data in Liver Disease and on a small human case-controlled trial ex-US in Psoriasis.  Additional patents are expected in a wide range of inflammatory diseases, including an ophthalmic disease, prenatal care and CAR-T (immuno-oncology). They are also exploring the use of their agents to prevent relapse/recurrence in several forms of cancer.

 

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Dr Ira C. Spector, CEO will deliver Greene Street's "Elevator" Pitch to the Group

8:20 - A Panel will address three major issues crucial to helping the Company reach the next level.

9:00 - Open discussion: members and guests

 


 LinkedIn   Bookmark and Share